Header cover image

U.S. Biotech Industry Analysis

UpdatedApr 25, 2024
DataAggregated Company Financials
Companies580
  • 7D1.0%
  • 3M-3.4%
  • 1Y0.7%
  • YTD-3.2%

The Biotech industry is up 1.0% in the last week, with AbbVie up 1.6%. During this same period, the BioMarin Pharmaceutical underperformed, falling 8.8%. The industry has been flat over the past 12 months despite the gain this week. Looking forward, earnings are forecast to grow by 21% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 26 Apr 2024US$1.1tUS$164.2b-US$23,382,193,080.9720.1x-46x6.6x
Sun, 24 Mar 2024US$1.2tUS$164.3b-US$23,936,586,653.3521.4x-48.6x7.1x
Tue, 20 Feb 2024US$1.2tUS$169.1b-US$20,394,485,082.3215.7x-57.5x6.9x
Thu, 18 Jan 2024US$1.4tUS$204.8b-US$22,506,707,794.0018.8x-63.3x7x
Sat, 16 Dec 2023US$1.4tUS$204.7b-US$22,119,635,723.0019.2x-61x6.6x
Mon, 13 Nov 2023US$1.2tUS$204.5b-US$21,996,116,562.0018.5x-54.6x5.9x
Wed, 11 Oct 2023US$1.3tUS$207.4b-US$13,069,383,940.0017.3x-96.7x6.1x
Fri, 08 Sep 2023US$1.3tUS$207.5b-US$12,639,999,993.0017.3x-100.8x6.1x
Sun, 06 Aug 2023US$1.3tUS$210.2b-US$10,135,599,050.0015.6x-124.3x6x
Tue, 04 Jul 2023US$1.1tUS$186.3b-US$16,037,705,056.0013.4x-69.9x6x
Thu, 01 Jun 2023US$1.1tUS$185.9b-US$16,012,100,305.0011.4x-69.8x6x
Sat, 29 Apr 2023US$1.2tUS$197.1b-US$6,647,559,484.0013.7x-174.1x5.9x
Mon, 27 Mar 2023US$1.1tUS$199.3b-US$3,667,886,514.0013.4x-309x5.7x
Wed, 22 Feb 2023US$1.1tUS$202.5b-US$166,298,506.0016.4x-6829.5x5.6x
Fri, 20 Jan 2023US$1.2tUS$203.7bUS$1.8b14.2x658.6x5.7x
Sun, 18 Dec 2022US$1.2tUS$203.3bUS$1.6b14.4x712.9x5.7x
Tue, 15 Nov 2022US$1.1tUS$202.2bUS$1.1b14.9x1009.4x5.5x
Thu, 13 Oct 2022US$1.0tUS$205.9bUS$5.3b15.2x195.3x5x
Sat, 10 Sep 2022US$1.1tUS$206.4bUS$6.2b15.6x177.5x5.3x
Mon, 08 Aug 2022US$1.1tUS$211.4bUS$8.4b16.7x131.8x5.3x
Wed, 06 Jul 2022US$1.1tUS$211.7bUS$10.9b16.8x98.6x5.1x
Fri, 03 Jun 2022US$994.0bUS$212.5bUS$11.1b15.2x89.4x4.7x
Sun, 01 May 2022US$1.0tUS$200.4bUS$6.7b16.9x151.5x5.1x
Tue, 29 Mar 2022US$1.3tUS$221.5bUS$11.8b19.1x107.6x5.7x
Thu, 24 Feb 2022US$1.2tUS$216.0bUS$6.3b21.3x193.4x5.6x
Sat, 22 Jan 2022US$1.2tUS$212.0bUS$2.5b23.1x493.9x5.8x
Mon, 20 Dec 2021US$1.5tUS$211.9bUS$2.8b26.1x524x6.9x
Wed, 17 Nov 2021US$1.5tUS$212.2bUS$3.8b26.9x383.5x6.9x
Fri, 15 Oct 2021US$1.5tUS$196.3b-US$2,594,144,740.0023.8x-571.3x7.5x
Sun, 12 Sep 2021US$1.6tUS$196.4b-US$2,267,737,004.5621.1x-697.6x8.1x
Tue, 10 Aug 2021US$1.6tUS$197.0b-US$1,565,512,785.5822.6x-1020.3x8.1x
Mon, 03 May 2021US$1.4tUS$174.8b-US$11,096,405,382.5522.2x-127.4x8.1x
Price to Earnings Ratio

-127.4x


Total Market Cap: US$1.4tTotal Earnings: -US$11,096,405,382.55Total Revenue: US$174.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -27.9x202220232024
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.2x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Revenues have also declined 2.1% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.21%
Healthcare1.41%
Biotech1.01%
Biotech1.01%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$167.291.6%
+US$4.7b
12.4%PE61.5x
AMGN AmgenUS$269.382.5%
+US$3.6b
12.1%PE21.5x
SGEN SeagenUS$228.744.5%
+US$1.8b
76.5%PS18.8x
BIIB BiogenUS$202.466.3%
+US$1.8b
-31.1%PE25.3x
BGNE BeiGeneUS$148.5612.6%
+US$1.7b
-41.9%PS6.3x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

SRPT

US$127.39

Sarepta Therapeutics

7D

9.3%

1Y

4.3%

BMRN

US$82.17

BioMarin Pharmaceutical

7D

-8.8%

1Y

-11.1%

BIIB

US$202.46

Biogen

7D

6.3%

1Y

-31.1%

MDGL

US$194.38

Madrigal Pharmaceuticals

7D

-12.5%

1Y

-36.2%

BGNE

US$148.56

BeiGene

7D

12.6%

1Y

-41.9%

LEGN

US$44.42

Legend Biotech

7D

-5.7%

1Y

-35.5%

INCY

US$51.18

Incyte

7D

-3.1%

1Y

-30.5%

ABBV

US$167.29

AbbVie

7D

1.6%

1Y

12.4%

AMGN

US$269.38

Amgen

7D

2.5%

1Y

12.1%

BHVN

US$38.54

Biohaven

7D

-8.6%

1Y

196.5%

EXAS

US$58.79

Exact Sciences

7D

-7.4%

1Y

-7.3%

GRPH

US$22.26

Graphite Bio

7D

539.7%

1Y

861.6%

SGEN

US$228.74

Seagen

7D

4.5%

1Y

76.5%